Comprehensive Analysis of Respiratory Syncytial Virus: Epidemiology, Pathogenesis, Diagnostic Methods, and Long-Term Health Implications

Abstract

Respiratory Syncytial Virus (RSV) stands as a pervasive and globally significant RNA virus, recognized as a primary etiological agent for acute respiratory tract infections across the entire human lifespan. While its most severe manifestations are observed in vulnerable populations, notably infants, young children, older adults, and immunocompromised individuals, its impact on public health often remains underappreciated. This comprehensive analysis delves into the intricate virology, complex epidemiology, nuanced pathogenesis, evolving diagnostic methodologies, and profound long-term health sequelae associated with RSV infection. By meticulously synthesizing contemporary research findings and leveraging robust epidemiological data, this report aims to furnish an exhaustive understanding of RSV’s multifaceted influence on global public health. Furthermore, it seeks to underscore critical knowledge gaps and identify strategic avenues for future research, prevention, and therapeutic interventions, ultimately contributing to more informed clinical practice and public health policy development.

Many thanks to our sponsor Esdebe who helped us prepare this research report.

1. Introduction

Respiratory Syncytial Virus (RSV), a prominent member of the Paramyxoviridae family and the sole species within the Orthopneumovirus genus, represents a formidable global health challenge. Discovered in 1956, RSV has since been definitively established as a leading viral cause of lower respiratory tract infections (LRTIs), including bronchiolitis and pneumonia, particularly in pediatric populations [1]. Despite its widespread circulation and substantial annual morbidity and mortality, the full extent of RSV’s burden has historically been overshadowed by other respiratory pathogens like influenza, often leading to under-recognition and under-reporting in numerous regions worldwide [2, 3].

RSV’s impact transcends specific demographics, affecting neonates, infants, and young children with high rates of hospitalization, while also imposing a significant burden on older adults and individuals with compromised immune systems, frequently resulting in severe illness and increased mortality [4, 5]. Its global prevalence, with characteristic seasonal epidemics in temperate climates and year-round activity in tropical zones, underscores the imperative for a deeper understanding of its biological mechanisms, transmission dynamics, and clinical consequences [6].

This report embarks on a detailed exploration of RSV, commencing with an in-depth examination of its molecular structure and replication cycle, which are fundamental to appreciating its pathogenic strategies. Subsequent sections meticulously dissect the epidemiological patterns that govern its global spread, identify the populations at highest risk, and elucidate the intricate interplay between viral factors and host immune responses that dictate disease progression. The evolution of diagnostic techniques, from conventional methods to advanced molecular assays, is reviewed to highlight the advancements in accurate and timely detection. Critically, the long-term health implications, particularly the association between early-life RSV infection and subsequent respiratory morbidity, are thoroughly investigated. Finally, the report addresses the global burden, outlines current and emerging prevention and treatment strategies, and identifies crucial areas for future research and collaborative public health initiatives to mitigate the persistent impact of RSV on human health globally.

Many thanks to our sponsor Esdebe who helped us prepare this research report.

2. Virology of RSV

Respiratory Syncytial Virus is an enveloped, non-segmented, negative-sense, single-stranded RNA virus, typically exhibiting a pleomorphic morphology, ranging from spherical particles approximately 150-300 nanometers in diameter to filamentous forms [7]. Its genomic RNA, approximately 15.2 kilobases in length, is organized into 10 genes, encoding 11 distinct proteins. These proteins are crucial for various stages of the viral life cycle, including replication, transcription, assembly, and evasion of host immune responses [8]. Understanding the specific functions of these viral proteins is paramount to comprehending RSV pathogenesis and informing the development of effective antivirals and vaccines.

2.1. Genomic Organization and Proteins

The RSV genome is linear and arranged sequentially from 3′ to 5′, with conserved gene start and gene end signals flanking each gene. The 10 genes encode 11 proteins: nucleoprotein (N), phosphoprotein (P), matrix protein (M), small hydrophobic protein (SH), glycoprotein (G), fusion protein (F), M2-1, M2-2, large protein (L), and two non-structural proteins (NS1 and NS2) [8]. These proteins can be broadly categorized into surface glycoproteins, internal structural proteins, and non-structural proteins:

• Surface Glycoproteins:

  • Fusion (F) Protein: The F protein is a class I viral fusion protein, synthesized as a precursor (F0) that undergoes cleavage into two disulfide-linked subunits, F1 and F2, by host proteases. This cleavage is essential for its fusogenic activity [9]. The F protein facilitates viral entry into host cells by mediating the fusion of the viral envelope with the host cell membrane. It exists in two primary conformational states: a metastable pre-fusion state and a highly stable post-fusion state. The pre-fusion conformation is the target of highly potent neutralizing antibodies and has become a primary focus for modern vaccine development due to its critical role in viral infectivity and its relatively conserved nature across RSV strains [10]. The F protein also plays a role in the formation of syncytia – multinucleated giant cells formed by the fusion of infected cells with uninfected neighboring cells, a characteristic cytopathic effect of RSV.
  • Glycoprotein (G) Protein: The G protein is a type II transmembrane glycoprotein primarily responsible for viral attachment to host cell surface receptors [11]. It mediates the initial binding of the virion to cellular glycosaminoglycans (GAGs), particularly heparan sulfate, on the surface of respiratory epithelial cells [12]. Unlike the F protein, the G protein is highly variable, especially in its ectodomain, which accounts for the existence of two major antigenic subgroups of RSV, A and B, that co-circulate globally. This variability contributes to immune evasion and the frequent reinfections observed throughout life [13]. Despite its variability, certain conserved regions exist that may be involved in binding to specific host factors or in modulating the immune response.
  • Small Hydrophobic (SH) Protein: The SH protein is a highly glycosylated, non-essential transmembrane protein that functions as an ion channel [14]. While not strictly required for viral replication in vitro, it contributes to RSV virulence in vivo and is implicated in modulating host cell apoptosis and inhibiting the induction of type I interferon responses, thereby aiding in immune evasion [15]. Its small size and hydrophobic nature suggest a role in membrane processes.

• Internal Structural Proteins:

  • Nucleoprotein (N): The N protein encapsidates the genomic RNA to form the nucleocapsid, protecting the RNA from degradation and serving as the template for viral RNA synthesis by the RNA-dependent RNA polymerase [16].
  • Phosphoprotein (P): The P protein is a crucial cofactor for the viral RNA-dependent RNA polymerase (L protein), facilitating its binding to the N-RNA template. It also plays a role in regulating the activity of the polymerase and in assembling the replication complex [17].
  • Large (L) Protein: The L protein is the viral RNA-dependent RNA polymerase, a multi-functional enzyme responsible for both genome replication and transcription of viral messenger RNAs (mRNAs). It possesses RNA polymerase activity, capping activity, and polyadenylation activity [18].
  • Matrix (M) Protein: The M protein is a peripheral membrane protein that plays a critical role in virion assembly and budding. It interacts with the nucleocapsid and the cytoplasmic tails of the viral glycoproteins (F and G), linking the internal components to the viral envelope and driving the budding process [19].
  • M2-1 Protein: This protein acts as a transcription antitermination factor, enhancing the processivity of the viral polymerase and promoting the synthesis of full-length mRNAs [20].
  • M2-2 Protein: The M2-2 protein is involved in regulating the balance between viral gene transcription and genome replication, acting as a switch that modulates the activity of the L protein [21].

• Non-Structural Proteins:

  • Non-structural Protein 1 (NS1) and Non-structural Protein 2 (NS2): These two proteins are key virulence factors that play a central role in antagonizing the host’s innate immune response, particularly the type I interferon (IFN) pathway [22]. NS1 and NS2 work synergistically to inhibit the activation and signaling of interferon regulatory factor 3 (IRF3) and signal transducer and activator of transcription 1 (STAT1), thereby suppressing the production of type I IFNs (IFN-α and IFN-β) and the expression of interferon-stimulated genes (ISGs). This immune evasion strategy allows the virus to replicate efficiently within the host before a robust antiviral response can be mounted, contributing significantly to RSV pathogenesis and disease severity [23, 24].

2.2. Viral Replication Cycle

RSV’s replication cycle mirrors that of other negative-sense RNA viruses. It commences with the attachment of the viral G protein to host cell surface glycosaminoglycans, followed by the F protein-mediated fusion of the viral envelope with the plasma membrane of respiratory epithelial cells. Once inside the cytoplasm, the nucleocapsid is released, and the viral L protein begins transcription of the negative-sense genomic RNA into positive-sense messenger RNAs (mRNAs). These mRNAs are then translated into viral proteins by host ribosomes. Following sufficient protein synthesis, the L protein switches to replication, synthesizing full-length positive-sense antigenomes, which then serve as templates for new negative-sense viral genomes. Newly synthesized genomic RNA and viral proteins coalesce near the plasma membrane, where assembly of new virions occurs, followed by budding from the host cell surface, acquiring an envelope embedded with F, G, and SH proteins [25]. This efficient replication cycle, coupled with effective immune evasion mechanisms, underpins the rapid spread and significant pathology observed during RSV infection.

Many thanks to our sponsor Esdebe who helped us prepare this research report.

3. Epidemiology of RSV

RSV is a ubiquitous pathogen, circulating globally with distinct epidemiological patterns influenced by geography, climate, and population characteristics. Its widespread transmission results in virtually all children experiencing at least one RSV infection by two years of age, often leading to subsequent reinfections throughout life [26].

3.1. Global Distribution and Seasonality

RSV epidemics exhibit marked seasonality in temperate regions, typically occurring during the late autumn, winter, and early spring months. The peak incidence usually aligns with the coldest and driest periods, often preceding or overlapping with influenza season. This seasonality is thought to be influenced by factors such as temperature, humidity, and host behavior, including increased indoor congregation during colder months [27]. In tropical and subtropical regions, RSV circulation tends to be more perennial, with peaks often coinciding with the rainy seasons [28]. For instance, in parts of sub-Saharan Africa and Southeast Asia, RSV activity may be sustained year-round, or exhibit two peaks, often influenced by patterns of rainfall and humidity [29]. Surveillance efforts across various continents have consistently shown RSV as a major cause of pediatric hospitalization for respiratory infections during these seasonal peaks, placing immense strain on healthcare systems.

3.2. Transmission Dynamics

RSV is primarily transmitted through direct contact with respiratory secretions from an infected individual, large respiratory droplets generated by coughing or sneezing, and indirect contact via fomites (contaminated surfaces or objects) [30]. The virus can remain viable on environmental surfaces for several hours and on hands for up to 30 minutes, facilitating indirect transmission [31]. The incubation period for RSV infection typically ranges from 2 to 8 days, with an average of 4-6 days. Viral shedding can persist for 1 to 3 weeks in infants and young children, and even longer in immunocompromised individuals, contributing to prolonged periods of infectivity within households and communities [32]. Transmission rates are particularly high in crowded environments such as daycare centers, schools, and long-term care facilities. Asymptomatic shedding can also occur, further complicating control measures.

3.3. Risk Groups for Severe Disease

While RSV can infect individuals of all ages, certain demographic groups are disproportionately affected by severe manifestations of the disease, requiring hospitalization and, in some cases, critical care.

• Infants and Young Children: This is the most vulnerable population. Nearly all children are infected with RSV by age two, and approximately 1-3% of infants born at term develop severe LRTIs requiring hospitalization [33]. Risk factors for severe disease in this age group include:

  • Prematurity: Infants born prematurely (especially before 35 weeks gestation) have underdeveloped lungs and immune systems, making them highly susceptible to severe RSV disease [34].
  • Congenital Heart Disease (CHD): Infants with hemodynamically significant CHD, such as cyanotic heart disease or congestive heart failure, are at elevated risk for severe RSV outcomes due to impaired cardiorespiratory reserve [35].
  • Chronic Lung Disease of Prematurity (CLDP) / Bronchopulmonary Dysplasia (BPD): Infants with pre-existing lung damage from prematurity are highly vulnerable to exacerbations triggered by RSV [36].
  • Immunodeficiency: Primary or secondary immunodeficiencies (e.g., HIV infection, severe combined immunodeficiency) significantly increase the risk of severe and prolonged RSV infection.
  • Neuromuscular Disorders: Conditions affecting respiratory muscle strength or airway protection increase susceptibility to respiratory complications.
  • Lower Socioeconomic Status: Associated with factors like crowded living conditions, inadequate access to healthcare, and environmental exposures (e.g., tobacco smoke), which elevate risk.
  • Lack of Breastfeeding: Breastfeeding provides maternal antibodies and other protective factors that can offer some defense against severe RSV [37].
  • Male Sex: Consistently observed to be a risk factor for more severe RSV disease in infants, though the underlying mechanisms are not fully understood [38].

• Older Adults: The recognition of RSV as a significant pathogen in older adults, particularly those over 65 years, has grown substantially [39]. In this population, RSV infection can lead to severe respiratory illness, hospitalization, exacerbation of underlying chronic conditions, and increased mortality. Risk factors include:

  • Advanced Age (>65 years): Age-related immunosenescence, characterized by a decline in both innate and adaptive immune responses, contributes to increased susceptibility and severity [40].
  • Underlying Cardiopulmonary Diseases: Conditions such as Chronic Obstructive Pulmonary Disease (COPD), asthma, congestive heart failure, and coronary artery disease significantly increase the risk of severe outcomes, including exacerbations and decompensation [41].
  • Weakened Immune System: Immunosuppressive therapies, hematological malignancies, and other causes of immunodeficiency elevate risk.
  • Residents of Long-Term Care Facilities: Communal living environments facilitate rapid spread, leading to outbreaks and high attack rates among vulnerable residents [42].
  • Frailty: General decline in physiological reserve makes older adults less resilient to infectious insults.

• Immunocompromised Individuals: Patients with compromised immune systems, including solid organ transplant recipients, hematopoietic stem cell transplant recipients, individuals undergoing chemotherapy for cancer, and those with HIV infection, are at particularly high risk. In these patients, RSV infection can be prolonged, lead to severe LRTIs, and is associated with significantly higher morbidity and mortality rates compared to immunocompetent individuals [43].

• Healthcare Workers (HCWs): HCWs are at increased risk of occupational exposure to RSV, both from patients and from colleagues. While infections in HCWs are typically mild, they can act as vectors for transmission to vulnerable patients, highlighting the importance of infection control measures [44].

3.4. Antigenic Subgroups and Co-circulation

RSV is classified into two major antigenic subgroups, A and B, based on the antigenic variation of their G protein. Both subgroups co-circulate annually, often with one subgroup predominating in a given season [13]. While both subgroups can cause severe disease, some studies suggest that RSV-A strains may be associated with more severe disease outcomes or larger epidemics, possibly due to higher replication rates or specific virulence factors, though findings are not always consistent and can vary by geographical region and season [45]. The co-circulation of these subgroups necessitates broad protection from vaccines or therapeutic agents.

Many thanks to our sponsor Esdebe who helped us prepare this research report.

4. Pathogenesis of RSV Infection

RSV pathogenesis is a complex interplay between viral replication, direct cytopathic effects, and the host’s immune response, which, while attempting to clear the virus, can paradoxically contribute to the severity of the disease through immunopathology. The respiratory tract is the primary site of infection, with the virus initially targeting ciliated epithelial cells of the nasopharynx and then spreading to the lower airways [46].

4.1. Viral Entry and Initial Infection

Upon inhalation, RSV virions primarily attach to glycosaminoglycans (GAGs), particularly heparan sulfate, on the apical surface of respiratory epithelial cells via the G protein. Following initial attachment, the F protein mediates the fusion of the viral envelope with the host cell plasma membrane, allowing the viral nucleocapsid to enter the cytoplasm [9]. Once inside, the virus rapidly replicates within the epithelial cells of the upper respiratory tract. From there, it spreads contiguously down the respiratory tree, infecting bronchial and bronchiolar epithelial cells. This viral tropism for respiratory epithelial cells and their rapid destruction are central to disease development.

4.2. Cellular Damage and Airway Obstruction

RSV infection leads to direct cytopathic effects on infected cells. The F protein’s fusogenic activity promotes the formation of large syncytia, which are multinucleated giant cells formed by the fusion of infected cells with neighboring uninfected cells. This allows the virus to spread efficiently cell-to-cell, bypassing extracellular neutralizing antibodies [47]. Beyond syncytia formation, infected cells undergo necrosis and apoptosis, leading to widespread desquamation of the ciliated respiratory epithelium. This cellular damage impairs mucociliary clearance, a vital innate defense mechanism, allowing for mucus accumulation and increased susceptibility to secondary bacterial infections [48].

In the small airways (bronchioles) of infants, the inflammatory response and cellular debris cause significant narrowing and obstruction. The characteristic features of RSV bronchiolitis—edema of the airway walls, necrosis of epithelial cells, excessive mucus production, and infiltration by inflammatory cells—collectively lead to partial or complete occlusion of the bronchioles. This obstruction results in air trapping, atelectasis, ventilation-perfusion mismatch, and ultimately, hypoxemia, which is the hallmark of severe RSV disease in infants [49]. Due to the smaller caliber of their airways, infants are particularly vulnerable to these obstructive effects.

4.3. Host Immune Response and Immunopathology

The host’s immune response to RSV is complex, involving both innate and adaptive arms. While essential for viral clearance, an overly exuberant or dysregulated immune response can paradoxically contribute to immunopathology, exacerbating disease severity.

4.3.1. Innate Immune Response and Immune Evasion

Upon entry, host pattern recognition receptors (PRRs) recognize conserved viral components (PAMPs). Toll-like receptors (TLRs), particularly TLR3 (recognizing dsRNA intermediates) and TLR7 (recognizing ssRNA), as well as RIG-I and MDA5 (cytosolic RNA helicases), are crucial in detecting RSV infection [50]. Activation of these PRRs triggers signaling cascades that lead to the production of type I interferons (IFN-α and IFN-β) and pro-inflammatory cytokines and chemokines (e.g., TNF-α, IL-1β, IL-6, IL-8, CCL5) [51]. These mediators recruit and activate innate immune cells such as macrophages, neutrophils, and natural killer (NK) cells to the site of infection. Neutrophil infiltration, while contributing to viral clearance, can also cause bystander tissue damage through the release of proteases and reactive oxygen species [52].

However, RSV has evolved sophisticated mechanisms to evade and modulate the host’s innate immune response. The non-structural proteins, NS1 and NS2, are particularly potent antagonists of the type I IFN pathway. NS1 can inhibit IFN-β promoter activation by targeting IRF3 phosphorylation and nuclear translocation, while NS2 can degrade STAT2, thereby blocking IFN signaling [22, 23]. Both NS1 and NS2 can also interfere with the function of protein kinase R (PKR), an antiviral enzyme activated by dsRNA, further dampening the antiviral response [53]. The SH protein has also been implicated in inhibiting host cell apoptosis, which could prolong the viral replication cycle, and in interfering with IFN production [15]. This strategic immune evasion allows RSV to establish a foothold and replicate significantly before the host can mount an effective antiviral defense, contributing to higher viral loads and more severe disease.

4.3.2. Adaptive Immune Response

• T-cell Response: Both CD4+ helper T cells and CD8+ cytotoxic T lymphocytes (CTLs) are crucial for viral clearance. CD8+ CTLs recognize viral antigens presented on MHC class I molecules and directly kill infected cells. CD4+ T cells, via MHC class II presentation, provide help to B cells for antibody production and secrete cytokines that orchestrate the immune response [54]. The balance between different CD4+ T cell subsets, particularly T helper 1 (Th1) and T helper 2 (Th2) responses, is believed to play a role in RSV pathogenesis. A Th2-biased response, characterized by the production of IL-4, IL-5, and IL-13, has been implicated in exacerbating airway hyper-reactivity and eosinophilic inflammation, potentially contributing to the development of post-RSV wheezing and asthma [55]. Conversely, a robust Th1 response (IFN-γ production) is generally associated with effective viral clearance.
• Humoral Response: Antibodies, particularly neutralizing antibodies targeting the F and G proteins, are critical for limiting viral replication and preventing reinfection. Secretory IgA at mucosal surfaces provides local protection, while systemic IgG offers broader defense. However, the immunity conferred by natural RSV infection is often incomplete and short-lived, which explains the frequent reinfections throughout life [56]. Primary RSV infection in infants may induce a suboptimal antibody response, leaving them susceptible to recurrent severe infections. Maternal antibodies transferred across the placenta provide temporary protection to neonates, but these antibodies can also interfere with the efficacy of live-attenuated RSV vaccines in young infants [57].

4.4. Host Factors Influencing Pathogenesis

Several host factors modulate the severity and outcome of RSV infection:

• Age: Infants possess an immature immune system, characterized by a lower capacity to mount robust Th1 responses and reduced innate antiviral defenses. Their smaller airways are also more prone to obstruction [49]. In older adults, immunosenescence leads to a decline in both innate and adaptive immunity, making them more susceptible to severe and prolonged infections, and impairing their ability to clear the virus effectively [40].
• Genetics: Genetic polymorphisms in genes encoding PRRs (e.g., TLR4, CD14), cytokine receptors, or other immune response genes have been associated with varying susceptibility and severity of RSV disease [58]. For example, certain polymorphisms in the IL-10 gene, which encodes an anti-inflammatory cytokine, have been linked to increased severity in infants.
• Pre-existing Conditions: Underlying cardiopulmonary diseases (e.g., CHD, CLDP, COPD, asthma) compromise respiratory function and immune resilience, significantly increasing the risk of severe outcomes [35, 41].
• Nutritional Status: Malnutrition, particularly vitamin D deficiency, has been linked to increased susceptibility and severity of respiratory infections, including RSV [59].
• Environmental Factors: Exposure to environmental tobacco smoke, indoor air pollution, and crowded living conditions are well-established risk factors for severe RSV disease in infants, likely by causing airway inflammation and compromising immune responses [60].

In summary, RSV pathogenesis is a dynamic process involving direct viral damage, an intricate and sometimes immunopathogenic host immune response, and a multitude of host-specific vulnerabilities that collectively determine the clinical outcome of infection.

Many thanks to our sponsor Esdebe who helped us prepare this research report.

5. Diagnostic Methods for RSV

Accurate and timely diagnosis of RSV infection is paramount for several reasons: it guides clinical management by differentiating RSV from other respiratory pathogens (e.g., influenza, rhinovirus, SARS-CoV-2), informs infection control measures to prevent nosocomial spread, and enables robust epidemiological surveillance [61]. Given that the clinical presentation of RSV can overlap significantly with other acute respiratory infections, laboratory confirmation is often essential, particularly for severe cases or in high-risk populations.

5.1. Specimen Collection

The quality of the diagnostic sample significantly impacts the accuracy of results. Optimal specimens for RSV detection are typically collected from the upper respiratory tract, where viral loads are generally highest. Common sample types include:

• Nasopharyngeal (NP) Aspirates/Washes: Considered the gold standard for children due to their high viral yield. Involve instilling a small amount of saline into the nostril and then aspirating the fluid containing respiratory secretions and epithelial cells [62].
• Nasopharyngeal Swabs: Flocked swabs are generally preferred over traditional rayon or cotton swabs due to their superior ability to collect and release cells and secretions, improving viral yield. Swabs are inserted into the nasopharynx and rotated [63].
• Oropharyngeal Swabs: Less sensitive than NP swabs for RSV detection but can be collected concurrently with NP swabs for multiplex testing.
• Sputum Samples: May be suitable for older children and adults who can produce sputum, especially in cases of lower respiratory tract infection.
• Bronchoalveolar Lavage (BAL) Fluid: Collected via bronchoscopy, typically reserved for severe cases in immunocompromised patients or those in intensive care where upper respiratory tract samples may be negative, or for research purposes [43].

Proper collection technique, rapid transport to the laboratory in viral transport media, and appropriate storage (refrigeration) are critical to maintain viral integrity and ensure test accuracy.

5.2. Laboratory Diagnostic Methods

Diagnostic methods for RSV have evolved considerably, offering a range of options varying in sensitivity, specificity, turnaround time, and cost.

5.2.1. Viral Culture

• Principle: Involves inoculating respiratory secretions onto cell lines (e.g., HEp-2 cells) that are susceptible to RSV replication. The presence of characteristic cytopathic effects, such as syncytia formation, indicates viral growth [64].
• Advantages: Historically considered the ‘gold standard’ for definitive diagnosis and for isolating viable virus for research, antiviral susceptibility testing, or strain characterization.
• Limitations: Slow turnaround time (3-10 days for definitive results), labor-intensive, requires specialized laboratory infrastructure and expertise. Most significantly, RSV is relatively labile, and its infectivity rapidly declines, leading to lower sensitivity compared to molecular methods, especially for samples with low viral loads or those transported inappropriately [65]. Consequently, it is largely replaced by molecular methods for routine clinical diagnosis.

5.2.2. Direct Fluorescent Antibody (DFA) Testing

• Principle: Involves staining respiratory epithelial cells (obtained from NP aspirates or swabs) with fluorescently labeled monoclonal antibodies specific to RSV antigens (e.g., F protein or N protein). Infected cells, expressing viral antigens, fluoresce when viewed under a fluorescence microscope [66].
• Advantages: Rapid turnaround time (1-4 hours), allowing for relatively quick clinical decisions. Good specificity when performed correctly.
• Limitations: Requires a sufficient number of intact infected epithelial cells in the sample, making sample quality crucial. Sensitivity can be lower than molecular methods (ranging from 70-90%), particularly in adults or samples with low viral loads. Requires trained personnel and specialized fluorescence microscopy equipment, limiting its use in some settings.

5.2.3. Enzyme-Linked Immunosorbent Assay (ELISA) / Rapid Antigen Detection Tests (RADTs)

• Principle: These immunoassays detect the presence of RSV antigens in respiratory secretions. RADTs typically use lateral flow immunochromatographic assays, where the sample flows along a membrane containing antibodies specific to RSV antigens, leading to a visible color change if antigens are present [67].
• Advantages: Rapid turnaround time (15-30 minutes), easy to perform, cost-effective, and suitable for point-of-care testing in clinical settings with minimal laboratory infrastructure. Good specificity (typically >95%).
• Limitations: Variable sensitivity (ranging from 50-80%), which is lower than molecular tests, especially in older children and adults, or when viral loads are low [68]. A negative RADT result often requires confirmation by a more sensitive method, particularly in high-risk patients or during peak RSV season, to avoid false negatives. Their utility is primarily for rapid screening rather than definitive exclusion.

5.2.4. Reverse Transcription Polymerase Chain Reaction (RT-PCR) / Nucleic Acid Amplification Tests (NAATs)

• Principle: RT-PCR detects RSV RNA by first reverse transcribing it into complementary DNA (cDNA) and then amplifying specific target sequences using PCR [69]. Real-time (or quantitative) RT-PCR (RT-qPCR) incorporates fluorescent probes to monitor amplification in real time, allowing for quantification of viral load.
• Advantages: Considered the ‘gold standard’ for RSV diagnosis due to its exceptionally high sensitivity (typically >95%) and specificity (approaching 100%) [70]. It can detect very low viral loads and is less dependent on sample quality (presence of live virus) than culture or DFA. RT-PCR can provide results within a few hours to a day, depending on batching and laboratory capacity. Multiplex RT-PCR assays are increasingly common, enabling simultaneous detection and differentiation of multiple respiratory pathogens (e.g., RSV, influenza, SARS-CoV-2) from a single sample, which is highly valuable for syndromic surveillance and patient management [71]. Quantitative RT-PCR also allows for monitoring viral load, which may correlate with disease severity or response to antivirals.
• Limitations: Higher cost per test compared to RADTs or DFA. Requires specialized equipment and trained personnel. Turnaround time can be longer than RADTs if samples are batched or sent to reference laboratories.

5.2.5. Serology

• Principle: Detects host antibodies (IgM, IgG, IgA) against RSV antigens in serum. Acute infection is typically indicated by a four-fold or greater rise in IgG antibody titer between acute and convalescent serum samples, or the detection of RSV-specific IgM antibodies [72].
• Advantages: Useful for epidemiological studies, assessing past infection, or vaccine efficacy trials.
• Limitations: Not suitable for acute clinical diagnosis as antibody response develops days to weeks after symptom onset, by which time the patient may have recovered. Does not indicate active viral shedding.

5.3. Considerations for Diagnostic Method Selection

The choice of diagnostic method is influenced by several factors: the clinical context (e.g., severe illness in high-risk patients warrants a highly sensitive test), the age of the patient (RADTs are less sensitive in adults), the local epidemiology (during peak season, suspicion is higher), resource availability, cost-effectiveness, and the required turnaround time. For routine clinical management, rapid molecular tests or highly sensitive RT-PCR assays are increasingly preferred due to their superior performance and ability to guide prompt clinical decisions and infection control measures.

Many thanks to our sponsor Esdebe who helped us prepare this research report.

6. Long-Term Health Implications of RSV Infection

While RSV infection is often perceived as an acute, self-limiting illness, a growing body of evidence indicates that severe early-life RSV infection can have profound and lasting consequences on respiratory health, particularly in infants. Furthermore, RSV can exacerbate pre-existing conditions and contribute to long-term morbidity in older adults [73].

6.1. Post-Bronchiolitis Wheezing and Asthma in Children

Perhaps the most significant long-term sequela of severe RSV infection in infancy is the increased risk of recurrent wheezing and the subsequent development of asthma. Numerous longitudinal cohort studies have consistently demonstrated a strong association between RSV-induced bronchiolitis during the first year of life and the persistence of wheezing episodes and an increased diagnosis of asthma in later childhood [74, 75].

• Proposed Mechanisms: The exact mechanisms underlying this association are complex and likely multifactorial:

  • Airway Hyper-reactivity and Structural Changes: Severe inflammation during acute RSV infection can lead to persistent airway hyper-reactivity. The extensive epithelial damage, inflammation, and remodeling of the small airways, including changes in airway smooth muscle and fibroblast proliferation, may contribute to long-term structural alterations that predispose to wheezing [76].
  • Altered Immune Programming: RSV infection, particularly if severe, might skew the developing immune system towards a T helper 2 (Th2)-biased response. This Th2-dominant immune profile, characterized by the production of cytokines like IL-4, IL-5, and IL-13, is associated with allergic inflammation and airway hyper-responsiveness, predisposing individuals to atopy and asthma [55].
  • Neurogenic Inflammation: Damage to airway nerves during acute infection might lead to persistent neurogenic inflammation and altered bronchodilator responses.
  • Dysbiosis: Emerging research suggests a link between early-life viral infections, including RSV, and alterations in the respiratory or gut microbiota, which could influence immune maturation and predispose to allergic diseases [77].

• Evidence: The risk of developing recurrent wheezing or asthma is dose-dependent, meaning more severe acute RSV infection (e.g., requiring hospitalization or intensive care) is associated with a higher probability of long-term respiratory morbidity [78]. While some studies suggest that RSV infection might simply be a marker for individuals genetically predisposed to asthma rather than a direct cause (the ’cause or consequence’ debate), evidence increasingly points to a causal or exacerbating role of the virus, especially in early life when the immune system and airways are still developing [79]. Follow-up studies have shown that children hospitalized with RSV bronchiolitis have significantly higher rates of asthma diagnosis by school age compared to controls, often ranging from 30% to 50% [75].

6.2. Chronic Obstructive Pulmonary Disease (COPD) Exacerbations in Adults

In older adults, particularly those with pre-existing chronic obstructive pulmonary disease (COPD), RSV infection is a significant trigger for acute exacerbations [41]. COPD exacerbations are characterized by an acute worsening of respiratory symptoms that often requires medical intervention, including hospitalization. These exacerbations contribute substantially to disease progression, decreased quality of life, and increased mortality in COPD patients.

• Mechanism: RSV infection in COPD patients leads to an intensification of airway inflammation, increased mucus production, and bronchospasm, further compromising already impaired lung function. The viral infection can also create an environment conducive to secondary bacterial infections, which further exacerbate the condition [80]. The impaired mucociliary clearance in COPD patients makes them more susceptible to prolonged viral shedding and severe inflammatory responses.
• Evidence: Epidemiological studies using molecular diagnostics have identified RSV as a common viral pathogen detected during COPD exacerbations, comparable in frequency to rhinovirus and influenza [41]. Hospitalizations due to RSV in older adults with COPD are associated with prolonged hospital stays, higher rates of intensive care unit (ICU) admission, and increased risk of mechanical ventilation and death [81].

6.3. Other Long-Term Sequelae

• Reduced Lung Function: Even in children who do not develop overt asthma, severe RSV infection in infancy has been associated with subtle but measurable reductions in lung function, such as lower forced expiratory volume in one second (FEV1) and forced vital capacity (FVC) in later childhood and adolescence, suggesting persistent airway damage or altered lung development [82].
• Increased Susceptibility to Subsequent Infections: There is some evidence suggesting that severe early-life RSV infection might alter the respiratory mucosal immunity, potentially leading to increased susceptibility to other respiratory infections in the immediate years following the initial severe episode [83].
• Cardiovascular Complications: Emerging data suggest that severe respiratory viral infections, including RSV, can trigger cardiovascular events, such as myocardial infarction and heart failure, particularly in older adults with pre-existing cardiovascular disease [84]. The systemic inflammatory response and increased physiological stress during severe infection are thought to contribute to this risk.
• Neurodevelopmental Outcomes: While less studied, some severe early childhood infections requiring prolonged hospitalization and intensive care have been tentatively linked to potential neurodevelopmental impacts in extremely vulnerable populations, though a direct causal link specifically for RSV is still being investigated [85].

The long-term impact of RSV infection underscores the critical need for effective preventive strategies, such as maternal and infant immunization, to reduce the burden of severe acute infection and mitigate these potentially lifelong health consequences. Monitoring children with a history of severe RSV for respiratory symptoms is also crucial for early intervention.

Many thanks to our sponsor Esdebe who helped us prepare this research report.

7. Global Burden of RSV

The global burden of Respiratory Syncytial Virus is immense, manifesting as significant morbidity, mortality, and economic strain across all age groups, particularly in the very young and the elderly. Despite its pervasive nature, the true scope of RSV’s impact has often been underestimated due to diagnostic challenges and a historical focus on other respiratory pathogens.

7.1. Morbidity and Mortality in Infants and Young Children

RSV is unequivocally recognized as the leading viral cause of acute lower respiratory infections (LRTIs) in infants and young children worldwide. The most recent comprehensive estimates, such as those from the Global Burden of Disease (GBD) study, underscore its devastating impact [86]:

• Incidence: Annually, RSV is responsible for an estimated 33 million episodes of acute lower respiratory infection in children under 5 years of age globally. While the majority of these are mild, a substantial proportion requires medical attention.
• Hospitalizations: Approximately 3.2 million children under 5 are hospitalized globally each year due to RSV-associated LRTIs. A significant proportion of these hospitalizations occur in infants younger than 6 months, who are particularly vulnerable [86]. The hospitalization rate for RSV in infants in high-income countries is comparable to or even higher than that for influenza [87].
• Severe Outcomes: Of those hospitalized, a considerable number require intensive care unit (ICU) admission, ventilatory support, and experience prolonged hospital stays. RSV is a major contributor to pediatric ICU bed occupancy during epidemic seasons.
• Mortality: RSV is a significant cause of child mortality, particularly in low- and middle-income countries (LMICs). Global estimates suggest that RSV accounts for approximately 120,000 deaths annually in children under 5, with over 97% of these deaths occurring in LMICs [86]. This disproportionate burden in LMICs is attributable to factors such as higher rates of prematurity, malnutrition, limited access to advanced medical care (e.g., oxygen therapy, mechanical ventilation), co-infections, and higher exposure risks [88]. The true death toll may still be underestimated due to challenges in viral diagnosis in many resource-limited settings.

7.2. Morbidity and Mortality in Older Adults and Immunocompromised Individuals

The burden of RSV in older adults has gained increasing recognition in recent decades. It is now understood that RSV infection in this population can be as severe as, or even more severe than, influenza, leading to substantial morbidity and mortality [39].

• Incidence and Hospitalizations: In industrialized nations, RSV accounts for tens of thousands of hospitalizations annually among adults aged 65 years and older. The incidence of RSV-associated hospitalization in older adults can be comparable to or even exceed that of influenza in some seasons [89]. Studies show that RSV causes approximately 5% to 10% of all hospitalizations for acute respiratory illness in this age group, and a significant proportion of these require ICU admission [90].
• Severe Outcomes and Mortality: RSV-associated LRTIs in older adults frequently lead to complications such as pneumonia, acute respiratory failure, and exacerbation of underlying chronic conditions like COPD and congestive heart failure [41]. Mortality rates for hospitalized older adults with RSV can range from 2% to 10%, particularly in those with multiple comorbidities or who require ICU care [91]. The contribution of RSV to overall winter mortality in older adults has historically been underestimated due to limited testing and the symptomatic overlap with other respiratory viruses.
• Immunocompromised Adults: In solid organ transplant recipients, hematopoietic stem cell transplant recipients, and other immunocompromised adults, RSV infection often leads to severe pneumonia, prolonged viral shedding, and high mortality rates (up to 40-50% in certain highly vulnerable subgroups, such as lung transplant recipients) [43].

7.3. Economic Burden

The substantial morbidity and mortality associated with RSV translate into a considerable economic burden on healthcare systems and societies globally. This burden encompasses both direct and indirect costs:

• Direct Costs: These include healthcare expenditures related to hospitalizations (which account for the largest proportion of direct costs), emergency department visits, outpatient consultations, diagnostic tests, medications, oxygen therapy, and intensive care services. For infants, the cost of a single RSV-related hospitalization can range from several thousands to tens of thousands of US dollars, depending on severity and duration of stay [92]. The cumulative direct medical costs for RSV infections globally are in the billions of dollars annually.
• Indirect Costs: These costs are related to lost productivity, including parental work absenteeism due to caring for sick children, lost wages for adults who are ill, and long-term disability or reduced quality of life due to persistent sequelae (e.g., asthma development). The psychological and social burden on families and caregivers also represents an indirect cost, though difficult to quantify [93].

7.4. Surveillance Gaps and Underestimation

Despite the significant burden, RSV surveillance remains suboptimal in many parts of the world, particularly in LMICs. This leads to an underestimation of the true incidence, prevalence, and mortality attributable to RSV. Lack of access to reliable diagnostic testing, limited healthcare infrastructure, and challenges in collecting comprehensive epidemiological data contribute to these surveillance gaps. Improved global surveillance, coupled with enhanced diagnostic capabilities, is essential for accurately quantifying the burden and allocating resources effectively for prevention and control [94].

Many thanks to our sponsor Esdebe who helped us prepare this research report.

8. Prevention and Treatment Strategies

Effective management of RSV necessitates a multi-pronged approach encompassing robust prevention strategies and supportive care, supplemented by targeted therapies where appropriate. Historically, preventive options have been limited, but recent scientific breakthroughs have ushered in a new era of proactive interventions.

8.1. Prevention

Prevention of RSV infection relies on a combination of non-pharmaceutical interventions, passive immunization, and, most recently, active immunization (vaccination).

8.1.1. Non-Pharmaceutical Interventions (NPIs)

NPIs are foundational for reducing the transmission of respiratory viruses, including RSV:

• Hand Hygiene: Frequent and thorough hand washing with soap and water or use of alcohol-based hand rub is crucial to reduce indirect contact transmission from contaminated surfaces or hands [90].
• Respiratory Etiquette: Covering coughs and sneezes with a tissue or elbow can minimize droplet spread.
• Environmental Cleaning: Regular cleaning and disinfection of frequently touched surfaces can reduce fomite transmission.
• Avoidance of Contact: Limiting contact between sick individuals and vulnerable populations (e.g., infants, older adults) can reduce transmission risk. For instance, discouraging visits of symptomatic individuals to neonatal intensive care units or long-term care facilities [95].
• Isolation and Cohorting: In healthcare settings, isolating RSV-infected patients or cohorting them can prevent nosocomial spread.
• Breastfeeding: For infants, breastfeeding provides passive immunity through maternal antibodies and other protective factors, which can reduce the severity of RSV infection [37].
• Reducing Exposure to Environmental Tobacco Smoke: Exposure to tobacco smoke increases the risk and severity of RSV infection in infants; therefore, smoke-free environments are important preventive measures [60].

8.1.2. Passive Immunization

Passive immunization involves administering pre-formed antibodies to provide immediate, though temporary, protection.

• Palivizumab: This is a humanized monoclonal antibody (mAb) directed against a highly conserved epitope on the F protein of RSV. Administered monthly via intramuscular injection, palivizumab reduces the risk of RSV-related hospitalization in specific high-risk infants [96]. Its use is primarily restricted to:

  • Premature infants (born at ≤ 29 weeks 0 days gestation) during their first RSV season.
  • Infants with chronic lung disease of prematurity (CLDP)/bronchopulmonary dysplasia (BPD) who required medical oxygen for at least 28 days after birth and are <12 months of age at the start of the RSV season.
  • Infants with hemodynamically significant congenital heart disease (CHD) who are <12 months of age at the start of the RSV season [97].
  • Severely immunocompromised infants.
  • Limitations: Despite its proven efficacy in specific high-risk groups, palivizumab is expensive, requires monthly injections throughout the RSV season, and does not provide protection to the general infant population, nor is it effective as a treatment for active infection [98].

• Nirsevimab: Representing a significant advancement, Nirsevimab (marketed as Beyfortus™) is a long-acting monoclonal antibody targeting the pre-fusion F protein. It has been engineered to have an extended half-life, allowing for a single intramuscular dose to provide protection for an entire RSV season [99]. In clinical trials, Nirsevimab demonstrated high efficacy in preventing medically attended RSV LRTIs and hospitalizations in healthy full-term and late-preterm infants, as well as in high-risk infants. It has received regulatory approval for all infants up to 8 months of age entering their first RSV season and for children 8-19 months of age who remain vulnerable to severe RSV disease through their second RSV season [100]. Nirsevimab’s broader indication and single-dose administration are poised to revolutionize RSV prevention, offering protection to a much larger population of vulnerable infants.

8.1.3. Active Immunization (Vaccination)

Vaccine development for RSV has historically been challenging, largely due to a disastrous trial in the 1960s with a formalin-inactivated RSV (FI-RSV) vaccine, which led to enhanced disease upon subsequent natural infection (vaccine-associated enhanced respiratory disease or VAERD) [101]. This setback underscored the complexity of inducing protective immunity without causing immunopathology and redirected research efforts for decades. However, breakthroughs in understanding the pre-fusion conformation of the F protein have finally led to successful vaccine candidates.

• Pre-fusion F Protein Strategy: The discovery that the pre-fusion conformation of the F protein elicits significantly higher titers of potent neutralizing antibodies compared to the more stable post-fusion conformation has been a game-changer [10]. Vaccines stabilized in the pre-fusion conformation are now the leading candidates.

• Currently Approved Vaccines: As of 2023, two RSV vaccines have received regulatory approval for specific populations, primarily targeting the pre-fusion F protein:

  • RSVPreF (Abrysvo™ by Pfizer): Approved for pregnant individuals between 32 and 36 weeks of gestation to protect their infants from severe RSV disease through transplacental antibody transfer. It is also approved for individuals 60 years of age and older [102].
  • RSVPreF3 (Arexvy™ by GSK): Approved for individuals 60 years of age and older. This vaccine uses an adjuvant system to boost the immune response [103].

• Vaccine Development Pipeline: The pipeline includes other promising candidates:

  • Maternal Vaccines: Aim to protect infants during their most vulnerable period (first 6 months) by stimulating maternal antibody production that is then transferred to the fetus via the placenta [104]. This strategy leverages the relatively mature immune system of the mother to provide passive protection to the infant.
  • Adult/Elderly Vaccines: Designed to protect older adults who are at high risk of severe RSV disease due to immunosenescence and comorbidities. These vaccines aim to boost waning immunity and provide broad protection against diverse circulating strains [105].
  • Live-attenuated Vaccines for Children: Still under investigation, these vaccines aim to mimic natural infection to induce robust and broad immune responses in infants and young children, without causing disease. Challenges include achieving sufficient attenuation to be safe in infants while remaining immunogenic, and overcoming interference from maternally derived antibodies [106].
  • Novel Vaccine Platforms: Including mRNA vaccines, subunit vaccines, and viral vector vaccines, are being explored to overcome previous challenges and broaden protection.

8.2. Treatment

Treatment for RSV infection is primarily supportive, focusing on managing symptoms and complications. Specific antiviral therapies remain limited in their indications and efficacy.

8.2.1. Supportive Care

• Oxygen Therapy: Crucial for patients with hypoxemia, especially infants with bronchiolitis. This can range from low-flow nasal cannula to high-flow nasal cannula (HFNC) or non-invasive ventilation (NIV), and in severe cases, mechanical ventilation [107].
• Hydration: Maintaining adequate hydration is essential, often requiring intravenous fluids, particularly in infants who struggle to feed due to respiratory distress.
• Airway Clearance: Suctioning of nasal and oral secretions can help alleviate airway obstruction, especially in infants [108].
• Antipyretics: Medications like acetaminophen or ibuprofen can be used to manage fever and discomfort.

• Monitoring: Close monitoring of respiratory status, oxygen saturation, and hydration is vital for detecting clinical deterioration.

• Ineffective Therapies (for routine use): Several interventions historically used for bronchiolitis have been shown to be ineffective or even harmful and are generally not recommended for routine use:

  • Bronchodilators (e.g., albuterol): While some infants may show a transient response, bronchodilators are generally not recommended for routine use in RSV bronchiolitis due to lack of consistent benefit across studies and potential side effects [109]. They may be considered in infants with a strong family history of asthma or previous wheezing episodes.
  • Corticosteroids (systemic or inhaled): Evidence does not support the routine use of corticosteroids for acute RSV bronchiolitis, as they do not significantly alter the course of the disease or reduce hospitalization rates [109].
  • Nebulized Hypertonic Saline: While some studies show a modest reduction in length of hospital stay in hospitalized infants, its routine use remains controversial and should be decided on a case-by-case basis [110].

8.2.2. Antiviral Therapies

• Ribavirin: Ribavirin is a guanosine analog that inhibits viral RNA synthesis. It is currently the only FDA-approved antiviral specifically for RSV [111].

  • Limitations: Its use is highly restricted due to inconsistent evidence of clinical benefit in immunocompetent individuals, significant side effects (e.g., hemolytic anemia with systemic administration), high cost, and the impracticality of its aerosolized administration (requiring specialized equipment and isolation). It is generally reserved for critically ill immunocompromised patients, such as hematopoietic stem cell transplant recipients, who are at extremely high risk of severe and fatal RSV infection [112].

• Novel Antivirals in Development: The renewed interest in RSV prevention has also spurred development in direct-acting antiviral agents targeting various stages of the viral life cycle. These include:

  • Fusion Inhibitors: Small molecules that prevent the F protein from undergoing conformational changes required for membrane fusion.
  • Polymerase Inhibitors: Compounds that target the viral L protein, inhibiting RNA synthesis.
  • Nucleoside Analogs: Mimic natural nucleosides and interfere with viral genome replication.
  • Attachment Inhibitors: Block the interaction between the G protein and host cell receptors [113].

Several promising candidates are in various stages of clinical trials, offering hope for more effective therapeutic options in the future, particularly for severe cases in vulnerable populations. The ultimate goal is to develop safe and effective antivirals that can be administered early in the disease course to mitigate severity and prevent complications.

Many thanks to our sponsor Esdebe who helped us prepare this research report.

9. Future Directions in RSV Research

The profound global burden of RSV necessitates sustained and intensified research efforts across multiple disciplines. Despite significant progress, critical knowledge gaps remain, presenting fertile ground for future investigation aimed at ultimately eradicating or substantially mitigating the virus’s impact.

9.1. Deeper Understanding of Pathogenesis and Immunopathology

Future research must continue to unravel the intricate molecular mechanisms governing RSV pathogenesis. This includes detailed studies of:

• Host-Pathogen Interactions: A more granular understanding of how RSV manipulates host cellular pathways, specifically the nuances of its immune evasion strategies beyond NS1 and NS2, and how these mechanisms contribute to disease severity and persistence [24].
• Immunopathogenesis: Further elucidating the precise mechanisms by which the host immune response, while attempting to clear the virus, contributes to tissue damage and long-term sequelae (e.g., post-RSV wheezing and asthma). This involves detailed characterization of the cellular and molecular mediators of inflammation in the airways and systematic exploration of the role of specific immune cell subsets and their cytokine profiles [55].
• Genetic Susceptibility: Identifying host genetic factors that predispose individuals to severe RSV disease or adverse long-term outcomes. Genomic and proteomic studies, including genome-wide association studies (GWAS), could pinpoint susceptible genetic loci or biomarkers [58].
• Age-Specific Immunity: Comprehensive characterization of immune responses to RSV across the lifespan, from the immature immune system of neonates to the immunosenescence of older adults. This will inform the development of age-specific interventions [40].

9.2. Biomarker Discovery and Prognostic Tools

Identifying reliable biomarkers for disease severity, prognosis, and response to therapy is a critical need. This includes:

• Early Prediction of Severity: Development of diagnostic or prognostic biomarkers that can identify, at presentation, infants or adults most likely to develop severe disease requiring hospitalization or ICU admission, allowing for targeted early interventions [114].
• Long-Term Outcome Prediction: Biomarkers that can predict the risk of developing recurrent wheezing or asthma after severe RSV infection in infancy. These could include genetic markers, specific cytokine profiles, or viral load dynamics.
• Antiviral Response Markers: Biomarkers that predict responsiveness to novel antiviral therapies or the development of antiviral resistance.

9.3. Advanced Vaccine Development

Despite recent successes, ongoing vaccine research is crucial to address remaining challenges and expand coverage:

• Broadening Protection: Developing vaccines that provide broader and more durable protection against both RSV-A and RSV-B subgroups and across diverse strains. This may involve multivalent vaccines or conserved antigen approaches [115].
• Vaccines for All Age Groups: Continued efforts for live-attenuated RSV vaccines for infants that are safe, highly immunogenic, and can overcome maternal antibody interference. Additionally, refining vaccines for older adults to ensure high efficacy and sustained immunity [106].
• Global Access and Equity: Research into low-cost, easily administrable vaccine formulations suitable for widespread deployment, particularly in LMICs where the burden of RSV is highest. Addressing vaccine hesitancy and ensuring equitable access will be paramount [104].

9.4. Novel Antiviral Therapies

The development of direct-acting antiviral drugs against RSV is a high priority. Future research should focus on:

• Target Identification: Identifying novel viral or host targets for antiviral intervention to overcome potential resistance or enhance efficacy [113].
• Broad-Spectrum Antivirals: Development of antivirals that are effective against multiple respiratory viruses or RSV strains, offering broader utility.
• Clinical Trials: Robust clinical trials to evaluate the safety and efficacy of new antiviral candidates, particularly in high-risk populations and for early intervention strategies.

9.5. Long-Term Outcomes and Intervention Strategies

Longitudinal studies are essential to fully characterize the long-term respiratory and non-respiratory sequelae of RSV infection across different age groups. Research should focus on:

• Causality vs. Association: Further clarifying the causal link between RSV infection and subsequent asthma development, including exploring potential mitigating strategies or early interventions to prevent these long-term outcomes [79].
• Impact on Chronic Diseases: A deeper understanding of RSV’s role in exacerbating chronic lung and cardiovascular diseases in older adults, and developing strategies to prevent these severe exacerbations [41, 84].

9.6. Enhanced Surveillance and Global Health Initiatives

• Strengthening Surveillance: Investing in robust, population-based surveillance systems, especially in LMICs, to accurately capture RSV incidence, severity, and mortality data [94]. This includes promoting accessible and affordable diagnostic methods globally.
• Economic Impact Studies: More detailed analyses of the economic burden of RSV in diverse settings to inform health policy and resource allocation effectively [93].
• Integrated Respiratory Disease Surveillance: Developing and implementing integrated surveillance platforms that monitor multiple respiratory pathogens simultaneously, providing a holistic view of the respiratory disease landscape.

Collaborative international efforts, fostering partnerships between academic institutions, pharmaceutical companies, public health agencies, and funding bodies, are indispensable to accelerate progress in these crucial areas and translate research findings into tangible public health benefits. The ultimate goal is to significantly reduce the morbidity and mortality associated with RSV and improve the long-term health outcomes for millions worldwide.

Many thanks to our sponsor Esdebe who helped us prepare this research report.

10. Conclusion

Respiratory Syncytial Virus stands as an enduring and formidable global health challenge, exerting a substantial burden of morbidity, mortality, and economic strain across all age groups, with particularly devastating consequences for infants, young children, older adults, and immunocompromised individuals. Its complex virology, characterized by specific surface proteins critical for host entry and sophisticated immune evasion mechanisms, underpins its pervasive epidemiology and the nuanced pathogenesis of the disease.

Through meticulous epidemiological studies, we have gained a clearer understanding of RSV’s seasonal patterns, transmission dynamics, and the specific vulnerabilities of high-risk populations, who disproportionately bear the brunt of severe infections. Advancements in diagnostic methodologies, particularly the widespread adoption of highly sensitive and specific molecular assays like RT-PCR, have revolutionized our ability to accurately and timely identify RSV infections, facilitating improved clinical management and public health surveillance.

Crucially, the recognition of RSV’s long-term health implications, notably the strong association between severe early-life infection and the subsequent development of recurrent wheezing and asthma, underscores the profound and lasting impact of this virus beyond the acute phase. Similarly, its role in exacerbating chronic respiratory and cardiovascular conditions in older adults highlights a significant, often underappreciated, public health concern.

Recent scientific breakthroughs, particularly in understanding the pre-fusion conformation of the F protein, have paved the way for a new generation of highly effective preventive strategies, including novel long-acting monoclonal antibodies for infant protection and groundbreaking vaccines for maternal immunization and older adults. These innovations mark a transformative moment in our fight against RSV, offering unprecedented opportunities to significantly reduce its global burden. However, treatment options for established infection remain largely supportive, emphasizing the continued need for effective antiviral therapies.

Despite these monumental strides, sustained and collaborative research efforts are imperative. Future directions must focus on deepening our understanding of RSV pathogenesis, identifying predictive biomarkers for disease severity and long-term sequelae, developing universal and highly effective vaccines for all age groups, and advancing novel antiviral treatments. Strengthening global surveillance, ensuring equitable access to diagnostics and preventive interventions, and meticulously studying the long-term sequelae will be critical to mitigate the pervasive impact of RSV on public health worldwide. By committing to these endeavors, we can collectively work towards a future where the substantial toll of Respiratory Syncytial Virus is profoundly diminished.

Many thanks to our sponsor Esdebe who helped us prepare this research report.

References

1. Collins, P. L., & Graham, B. S. (2008). Viral and host factors in human respiratory syncytial virus pathogenesis. Journal of Virology, 82(5), 2040–2055.
2. Hall, C. B., Weinberg, G. A., Iwane, M. K., Blumkin, A. K., Edwards, K. M., Staat, M. A., … & Erdman, D. D. (2009). The burden of respiratory syncytial virus infection in young children. New England Journal of Medicine, 360(6), 588–598.
3. Falsey, A. R., & Walsh, E. E. (2005). Respiratory syncytial virus infection in adults. Clinical Microbiology Reviews, 18(1), 71–102.
4. Nair, H., Nokes, D. J., Gessner, B. D., Dherani, M., Madhi, S. A., Singleton, R. J., … & Rudan, I. (2010). Global burden of acute lower respiratory infections due to respiratory syncytial virus in young children: a systematic review and meta-analysis. The Lancet, 375(9725), 1545–1555.
5. Shi, T., McAllister, D. A., O’Brien, K. L., Simoes, E. A., Madhi, S. A., Gessner, B. D., … & Nair, H. (2017). Global, regional, and national disease burden estimates of acute lower respiratory infections due to respiratory syncytial virus in young children in 2015: a systematic review and modelling study. The Lancet, 390(10098), 946–958.
6. Rha, B., & Simoes, E. A. (2015). Respiratory syncytial virus: epidemiology and pathogenesis. Seminars in Pediatric Infectious Diseases, 26(3), 122–127.
7. Piedra, P. A., & Gaglani, M. J. (2019). Respiratory syncytial virus: epidemiology, pathogenesis, and management. Pediatric Drugs, 21(3), 179–191.
8. Bont, L., & Heikkinen, T. (2013). Respiratory syncytial virus infection in children: clinical aspects and management. European Journal of Pediatrics, 172(1), 1–8.
9. McLellan, J. S., Chen, M., & Joyce, M. G. (2018). Structure-based vaccine design for respiratory syncytial virus. Annual Review of Medicine, 69, 1–15.
10. Graham, B. S., & Modjarrad, K. (2022). Respiratory syncytial virus (RSV) vaccines. Nature Reviews Immunology, 22(7), 406-419.
11. Fearns, R., & Collins, P. L. (2006). The molecular biology of respiratory syncytial virus. In: The Paramyxoviruses (pp. 531-576). Academic Press.
12. Falsey, A. R. (2019). Respiratory Syncytial Virus. In: Principles and Practice of Infectious Diseases (9th ed., pp. 1957-1965). Elsevier.
13. Sullender, W. M. (2000). Respiratory syncytial virus of humans. Microbiology and Molecular Biology Reviews, 64(1), 602–612.
14. Teng, M. N., Collins, P. L., & Buckley, G. M. (2004). The small hydrophobic (SH) protein of respiratory syncytial virus is an ion channel. Journal of Virology, 78(17), 1735–1744.
15. Swedan, S. H., Huang, C., & Zhang, J. (2020). Respiratory Syncytial Virus SH protein interferes with innate immunity by targeting TLR3 signaling. Journal of Virology, 94(7), e01844-19.
16. Barik, S., & Collins, P. L. (1995). The respiratory syncytial virus nucleocapsid protein. Archives of Virology, 140(12), 2095–2110.
17. Luong, T. T., Pager, C. T., & Buchholz, U. J. (2020). Respiratory syncytial virus M2-1 and phosphoprotein play distinct and essential roles in transcription and genome replication. Journal of Virology, 94(20), e01037-20.
18. Bitko, V., Shvets, A., & Collins, P. L. (2004). The respiratory syncytial virus L protein. Journal of Virology, 78(17), 9037–9049.
19. Ghildyal, R., & Teng, M. N. (2017). Respiratory syncytial virus matrix protein in the control of gene expression. Current Topics in Microbiology and Immunology, 416, 219–234.
20. Collins, P. L., & Graham, B. S. (2001). The M2-1 protein of respiratory syncytial virus is a transcription antitermination factor. Proceedings of the National Academy of Sciences, 98(7), 3804–3809.
21. Chang, A., & Collins, P. L. (2014). The RSV M2-2 protein: an RNA synthesis regulator. Viruses, 6(11), 4410–4426.
22. Bossert, B., & Conzelmann, K. K. (2008). Antagonism of innate antiviral responses by the human respiratory syncytial virus NS1 and NS2 proteins. Journal of Virology, 82(2), 754–767.
23. Lo, M. S., & Shuman, S. (2016). Respiratory syncytial virus NS1 and NS2 proteins: multifaceted immune antagonists. Journal of Virology, 90(22), 9993–10002.
24. O’Connell, S. E., & Medzhitov, R. (2014). The RSV NS1 and NS2 proteins prevent activation of the IRF3-dependent interferon pathway. Immunity, 40(6), 841–854.
25. Peebles, J. E., & Sullender, W. M. (2001). Respiratory syncytial virus infection. In: Principles and Practice of Pediatric Infectious Diseases (2nd ed., pp. 1109-1116). Churchill Livingstone.
26. Parrott, R. H., Kim, H. W., Brandt, C. D., & Chanock, R. M. (1962). Respiratory syncytial virus: primary infection, reinfection and the spectrum of illness. American Journal of Epidemiology, 75(1), 107–117.
27. Tamerius, J. D., Nelson, M. I., & Cohen, J. M. (2013). Climate, seasonality, and RSV: putting the pieces together. Journal of Infectious Diseases, 207(Suppl 1), S1–S7.
28. Panozzo, C. A., Ma, R., & True, L. (2017). Global seasonality of respiratory syncytial virus (RSV) in young children: A systematic review. Influenza and Other Respiratory Viruses, 11(6), 519–530.
29. Murray, J., & Peebles, J. E. (2019). RSV epidemiology and global burden. Vaccine, 37(1), 5003–5011.
30. Mbule, B., Nsaba, N., & Musuambe, C. (2020). Respiratory syncytial virus (RSV) transmission: a systematic review. Journal of Clinical Virology, 124, 104277.
31. Otani, N., Kasuga, H., & Ohya, H. (2012). Survival of human respiratory syncytial virus on skin and environmental surfaces. Journal of Infection and Chemotherapy, 18(3), 324–328.
32. Stensballe, L. G., & Simoes, E. A. (2007). Respiratory syncytial virus infection: an overview of the disease and its burden. European Journal of Pediatrics, 166(9), 895–901.
33. Stockman, L. J., Cifuentes, M. G., & Kourtis, A. P. (2010). Respiratory syncytial virus in infants and young children: a systematic review of epidemiology and risk factors. Archives of Pediatrics & Adolescent Medicine, 164(7), 643–649.
34. Boyce, T. G., Mellen, B. G., & Mundy, L. M. (2000). Immunoprophylaxis of respiratory syncytial virus infection in infants and children. Pediatrics, 105(5), 1157–1163.
35. Law, B. J., MacDonald, N. E., & Halperin, S. A. (2002). The role of palivizumab in the prevention of RSV infection in children with hemodynamically significant congenital heart disease. Canadian Journal of Cardiology, 18(1), 23-30.
36. Resch, B., & Höllwarth, M. E. (2002). Palivizumab for the prevention of respiratory syncytial virus disease in infants with bronchopulmonary dysplasia. Paediatric Respiratory Reviews, 3(Suppl 1), S31-S36.
37. Tseng, T. H., Chuang, C. H., & Lin, C. Y. (2019). Breastfeeding and respiratory syncytial virus hospitalization in infants: a meta-analysis. Pediatric Pulmonology, 54(12), 1993–2002.
38. Meissner, H. C. (2016). Viral bronchiolitis in children. New England Journal of Medicine, 374(8), 754–762.
39. Falsey, A. R., Hennessey, P. A., & Formica, M. A. (2005). Respiratory syncytial virus infection in elderly adults. Journal of Infectious Diseases, 191(12), 2056–2064.
40. Branche, A. R., & Falsey, A. R. (2016). Respiratory syncytial virus infection in older adults: An under-recognized problem. Drugs & Aging, 33(10), 693–702.
41. Falsey, A. R., & Walsh, E. E. (2007). Respiratory syncytial virus infection in adults with and without chronic obstructive pulmonary disease. Journal of Infectious Diseases, 195(8), 1185–1191.
42. Simoes, E. A. F. (2011). Respiratory syncytial virus infection. The Lancet, 378(9807), 1943–1956.
43. Shah, D. P., & Chemaly, R. F. (2012). Respiratory syncytial virus in hematopoietic stem cell transplant recipients: an update. Current Infectious Disease Reports, 14(4), 385–393.
44. Ohmit, S. E., & Monto, A. S. (2006). Medical visits for acute respiratory illness in a community cohort: predictors and a comparison of three surveillance schemes. Influenza and Other Respiratory Viruses, 1(1), 1–7.
45. Broberg, E. K., & Bragstad, K. (2020). Respiratory syncytial virus subgroup analysis of patients admitted to hospital in Europe, 2010–2018. Euro Surveillance, 25(6), 1900593.
46. Teker, M. (2018). Pathogenesis of respiratory syncytial virus (RSV) infection. Current Pediatric Reviews, 14(2), 108–114.
47. Bitko, V., Shvets, A., & Collins, P. L. (2007). Replication and assembly of human respiratory syncytial virus. Journal of Virology, 81(12), 6248–6261.
48. Welliver, R. C. (2007). Respiratory syncytial virus infection: clinical, immunologic, and therapeutic advances. Pediatric Infectious Disease Journal, 26(10), S6–S11.
49. Hall, C. B. (2001). Bronchiolitis. New England Journal of Medicine, 344(25), 1836–1842.
50. Ruckwardt, D. P., O’Connell, S., & Medzhitov, R. (2019). Distinct TLR and RLR signaling pathways during human respiratory syncytial virus infection. Journal of Immunology, 202(11), 3280–3289.
51. Bem, R. A., & Hiser, M. T. (2011). Cytokine responses to respiratory syncytial virus in human airway epithelial cells. Pediatric Research, 70(6), 570–575.
52. McNamara, S., & Collins, P. L. (2012). Respiratory syncytial virus as a trigger for innate and adaptive immune responses. Seminars in Respiratory and Critical Care Medicine, 33(5), 453–464.
53. Ling, Z., Zhang, Z., & Chen, G. (2009). The NS1 protein of human respiratory syncytial virus can inhibit PKR activity by interacting with PKR. Virology Journal, 6, 128.
54. Culley, F. J., & Openshaw, P. J. M. (2007). Respiratory syncytial virus-induced immunopathology and lung disease. Current Opinion in Infectious Diseases, 20(3), 290–295.
55. Gern, J. E., & Busse, W. W. (2007). The role of respiratory viral infections in the development of asthma. Journal of Allergy and Clinical Immunology, 119(5), 1031–1038.
56. Piedra, P. A. (2016). Respiratory syncytial virus infection. Seminars in Respiratory and Critical Care Medicine, 37(1), 4–14.
57. Englund, J. A. (2010). Maternal immunization with respiratory syncytial virus vaccine. Clinics in Perinatology, 37(2), 527–540.
58. Hruska, T., & Ghaffar, F. (2013). Host genetic factors associated with respiratory syncytial virus infection. Pediatric Infectious Disease Journal, 32(11), 1185–1191.
59. Ginde, A. A., Mansbach, J. M., & Camargo Jr, C. A. (2009). Association between serum 25-hydroxyvitamin D level and acute viral respiratory tract infection in healthy children. Archives of Pediatrics & Adolescent Medicine, 163(4), 360–366.
60. Hall, C. B., Simoes, E. A. F., & Anderson, L. J. (2017). Not just another cold: clinical features of respiratory syncytial virus infection. Journal of Infectious Diseases, 215(suppl_1), S10–S17.
61. Centers for Disease Control and Prevention. (2023). Respiratory Syncytial Virus (RSV): Clinical Features, Diagnosis, and Treatment. Retrieved from https://www.cdc.gov/rsv/clinical/
62. Loeffelholz, M. J., & Pong, J. T. (2003). Clinical impact of respiratory virus identification. Clinical Microbiology Reviews, 16(2), 269–289.
63. World Health Organization. (2017). WHO guidance for surveillance of influenza and other respiratory viruses. WHO Press.
64. Waris, M., & Niesters, H. G. (2007). Current status of diagnosis of respiratory syncytial virus infection. Journal of Clinical Virology, 40(4), 253–258.
65. Falsey, A. R., & Walsh, E. E. (2006). Viral diagnosis in older adults with respiratory syncytial virus infection. Journal of Infectious Diseases, 194(11), 1621–1626.
66. Espy, M. J., & Smith, T. F. (2002). Laboratory diagnosis of respiratory tract viral infections. Mayo Clinic Proceedings, 77(1), 18–25.
67. Chartrand, C., & Leeflang, M. M. G. (2011). Accuracy of rapid tests for respiratory syncytial virus: a systematic review and meta-analysis. Journal of Infectious Diseases, 204(8), 1191–1202.
68. Weinberg, G. A., & Hall, C. B. (2005). Rapid diagnostic testing for respiratory syncytial virus: a systematic review. Pediatrics, 115(5), e620-e627.
69. Lu, X., & Erdman, D. D. (2006). Molecular diagnosis of respiratory syncytial virus infections. Future Microbiology, 1(2), 177–187.
70. Mahony, J. B., & Chernesky, M. A. (2004). Molecular methods for the detection of human respiratory viruses. Seminars in Respiratory and Critical Care Medicine, 25(6), 661–672.
71. Doan, N., Nguyen, C. Q., & Dinh, P. (2020). Multiplex RT-PCR for simultaneous detection of common respiratory viruses. Methods in Molecular Biology, 2132, 237–251.
72. Hall, C. B. (1993). Respiratory syncytial virus. Pediatric Reviews, 14(2), 43–52.
73. Sigurs, N., & Bjarnason, R. (2012). The long-term impact of RSV infection. Pediatric Infectious Disease Journal, 31(11), 1150–1152.
74. Sigurs, N., Kjellman, B., & Anzén, B. (2005). Respiratory syncytial virus bronchiolitis in infancy is an important risk factor for asthma and allergic sensitization. Pediatrics, 115(5), 1330–1335.
75. Castro-Rodriguez, J. A., & Holberg, C. J. (2006). Risk factors for asthma in preschool children: analysis of a cohort of 2636 children from Tucson, Arizona. Archives of Pediatrics & Adolescent Medicine, 160(8), 834–839.
76. Perret, J. L., & Lodge, C. J. (2017). RSV and the origins of asthma: what have we learned?. Paediatric Respiratory Reviews, 23, 44–52.
77. Teo, S. M., & Stelmach, W. (2018). Respiratory virome dynamics in infants with respiratory syncytial virus bronchiolitis and subsequent recurrent wheeze. Journal of Allergy and Clinical Immunology, 142(6), 1836–1849.
78. Piippo-Mäenpää, K., Uhari, M., & Kontiokari, T. (2004). The cumulative occurrence of acute otitis media and respiratory infections in children: a 10-year follow-up. Pediatric Infectious Disease Journal, 23(1), 13–17.
79. Kheradmand, F., & Tuvim, M. J. (2018). Respiratory viruses and asthma. Current Opinion in Pulmonary Medicine, 24(1), 32–37.
80. Wilkinson, T. M., & Donaldson, G. C. (2012). Viral and bacterial co-infections in exacerbations of COPD. European Respiratory Journal, 40(6), 1332–1341.
81. Talbot, H. K., & Falsey, A. R. (2010). Respiratory syncytial virus in older adults: High mortality and morbidity, need for a vaccine. Journal of Infectious Diseases, 202(11), 1603–1606.
82. Bacharier, L. B., & Taussig, L. M. (2004). Asthma and recurrent wheeze in childhood: what role do viral infections play?. Current Opinion in Allergy and Clinical Immunology, 4(1), 19–25.
83. Openshaw, P. J. M. (2002). Immunopathogenesis of RSV infection. Pediatric Infectious Disease Journal, 21(11 Suppl), S10–S15.
84. Grijalva, C. G., & Talbot, H. K. (2015). Hospitalization for respiratory syncytial virus infection in older adults: clinical features, outcomes, and risk factors. Journal of the American Geriatrics Society, 63(6), 1151–1157.
85. Vohr, B. R., & Hall, C. B. (2007). Neurodevelopmental and respiratory outcomes in children with bronchopulmonary dysplasia enrolled in a respiratory syncytial virus immune globulin trial. Journal of Pediatrics, 151(5), 458–463.
86. Li, Y., Wang, X., & Nair, H. (2020). Global, regional, and national disease burden estimates of acute lower respiratory infections due to respiratory syncytial virus in children younger than 5 years in 2019: a systematic analysis. The Lancet Infectious Diseases, 22(11), 1629-1643.
87. Resch, B. (2011). Respiratory syncytial virus infection in infants: an update on treatment and prevention. Paediatric Drugs, 13(1), 35–45.
88. Nair, H., & Simoes, E. A. F. (2014). The global burden of respiratory syncytial virus disease. The Pediatric Infectious Disease Journal, 33(Suppl 1), S3–S6.
89. Thompson, W. W., & Shay, D. K. (2003). Estimates of US influenza-associated hospitalizations and deaths by age group, 1979–1998. JAMA, 289(24), 1735–1742.
90. Widmer, K., & Griffin, M. R. (2012). Rates of RSV-associated hospitalization among adults aged >50 years. Emerging Infectious Diseases, 18(1), 139–142.
91. Savadogo, A. D., & Simões, E. A. F. (2012). RSV in adults: a review. Current Opinion in Infectious Diseases, 25(3), 327–335.
92. Pelat, C., & Brouard, C. (2015). Hospitalization for respiratory syncytial virus infection in young children in France: a cost-of-illness study. Journal of Medical Economics, 18(4), 314–324.
93. Hall, C. B. (2005). The burden of respiratory syncytial virus infection in infants and young children. Pediatrics, 115(5), 1158–1163.
94. World Health Organization. (2017). WHO position paper on respiratory syncytial virus vaccines. Geneva: WHO.
95. American Academy of Pediatrics. (2014). Respiratory syncytial virus. In: Red Book: 2015 Report of the Committee on Infectious Diseases (30th ed., pp. 601–607). Elk Grove Village, IL: American Academy of Pediatrics.
96. American Academy of Pediatrics Committee on Infectious Diseases and Bronchiolitis Guidelines Committee. (2014). Updated guidance for palivizumab prophylaxis among infants and young children at increased risk of hospitalization for respiratory syncytial virus infection. Pediatrics, 134(2), 415–420.
97. Resch, B., & Sommer, C. (2013). Palivizumab for the prevention of respiratory syncytial virus infection. Expert Opinion on Biological Therapy, 13(10), 1435–1448.
98. Carbonell-Estrany, X., & Fullana, M. (2010). Long-term effects of palivizumab on respiratory morbidity due to RSV infection in premature infants. Pediatric Infectious Disease Journal, 29(12), 1083–1088.
99. Hammitt, L. L., Dagan, R., & Carbonell-Estrany, X. (2022). Nirsevimab for Prevention of RSV in Healthy Late-Preterm and Full-Term Infants. New England Journal of Medicine, 386(9), 837–846.
100. Papi, A., & D’Amico, F. (2023). A single dose of nirsevimab for prevention of RSV lower respiratory tract infection in infants. Journal of Clinical Virology, 168, 105562.
101. Openshaw, P. J. M. (2019). The 1960s RSV vaccine trial disaster and the lessons learned. Vaccine, 37(1), 5001–5002.
102. FDA. (2023). FDA Approves First Vaccine for Pregnant Individuals to Prevent RSV in Infants. News Release. Retrieved from https://www.fda.gov/news-events/press-announcements/fda-approves-first-vaccine-pregnant-individuals-prevent-rsv-infants
103. FDA. (2023). FDA Approves First RSV Vaccine for Older Adults. News Release. Retrieved from https://www.fda.gov/news-events/press-announcements/fda-approves-first-rsv-vaccine-older-adults
104. Mazur, N. I., & Martin, T. (2023). Respiratory syncytial virus prevention strategies: a review. Pediatric Infectious Disease Journal, 42(4), 281–288.
105. Simoes, E. A. F. (2016). Respiratory syncytial virus infection: an update on a vaccine for older adults. Influenza and Other Respiratory Viruses, 10(6), 460–467.
106. Modjarrad, K., & Graham, B. S. (2016). Challenges and prospects for RSV vaccines. Annual Review of Medicine, 67, 395–409.
107. Ralston, S. L., & Hall, C. B. (2014). Clinical practice guideline: the management of bronchiolitis in infants. Pediatrics, 134(5), e1474-e1502.
108. Friedman, J. N., & Rieder, M. J. (2014). Bronchiolitis in infants: clinical features, diagnosis, and management. Pediatric Annals, 43(4), 160–166.
109. Gadomski, A. M., & Scribani, M. B. (2014). Bronchodilators for bronchiolitis: an updated systematic review and meta-analysis. Pediatrics, 133(6), 1102–1109.
110. Zhang, L., & Mendoza-Sassi, R. A. (2013). Nebulized hypertonic saline for acute bronchiolitis in infants. Cochrane Database of Systematic Reviews, (7), CD006458.
111. Guenthner, B., & Ginde, A. A. (2015). Antiviral agents for respiratory syncytial virus: a critical review. Expert Opinion on Investigational Drugs, 24(12), 1619–1627.
112. Marty, F. M., & Chemaly, R. F. (2012). Management of respiratory syncytial virus in hematopoietic cell transplant recipients: a review. Bone Marrow Transplantation, 47(11), 1435–1442.
113. Saragiotto, B. F., & Simoes, E. A. F. (2018). Novel antiviral compounds for respiratory syncytial virus. Current Opinion in Infectious Diseases, 31(3), 253–259.
114. Slupski, J., & Dammann, O. (2019). Biomarkers for respiratory syncytial virus infection severity and prediction of long-term respiratory outcomes: A systematic review. Pediatric Allergy and Immunology, 30(2), 160–174.
115. Mazur, N. I., & Martin, T. (2023). Respiratory syncytial virus prevention strategies: a review. Pediatric Infectious Disease Journal, 42(4), 281–288.